Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (3032)	7/15/2010 1:05:56 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

ARNA opened with a good UG and went trough the resistance at the $5 level,g> The stock is up 21.96% on volume >3x its ADV bigcharts.marketwatch.com The stock is benefiting from the fact than an FDA panel will discuss whether to approve VVUS' diet-drug Qnexa later today.<g> As previously mentioned, ARNA is also been helped by the FDA panel meeting yesterday that focused on the cardiovascular risks posed by GSK's Avandia.<g> Since ARNA's lorcaserin is believed to carry a lower CV risk. The ACTAY and TT remain unchanged.<g> Bernard